Annual report pursuant to Section 13 and 15(d)

RFS Pharma, LLC Acquisition (Tables)

v2.4.1.9
RFS Pharma, LLC Acquisition (Tables)
12 Months Ended
Dec. 31, 2014
Business Combinations [Abstract]  
Schedule of purchase price consideration

 

Purchased in-process research and development   $ 184,966  
Net book value of tangible assets acquired and liabilities assumed     (183 )
Goodwill     65,195  
Deferred tax liability     (65,195 )
Total purchase price   $ 184,783